Founded in 2014, Aledade offers a new model of primary care that keeps physicians right where they want to be: building strong, impactful relationships with their patients. Aledade has grown rapidly and currently partners with hundreds of practices responsible for nearly 1.2 million patients across 31 states to support the delivery of seamless, affordable, high-quality care.
The founding principle of Aledade stems from thousands of conversations with stakeholders from across the country: primary care providers are the foundation of an efficient and effective health care system.
At the heart of the Aledade model is the simple, but radical, idea that Aledade only succeeds when partner practices succeed in lowering costs to payers through better care for patients. By keeping patients and their healthcare providers at the center of all we do, Aledade envisions a more efficient, effective healthcare delivery system that’s good for patients, good for practices, and good for society.
Our team is at the heart of what we do. With a passion for public health and data-driven results, we are relentless in our mission to improve healthcare.
Aledade’s rapidly expanding network covers nearly 1.2 million patients in 31 states. Learn more about where we are and where we’re going.
In addition to Aledade CEO and Board Chair, Dr. Farzad Mostashari, Aledade’s Board Members include Dr. Bob Kocher, Julie Sunderland, and Jim Manzi.
Dr. Bob Kocher is a Partner at Venrock and focuses on healthcare IT and services investments. Additionally, he is a Consulting Professor at Stanford University School of Medicine, Senior Fellow and Advisory Board Member at the Leonard D. Schaeffer Center for Health Policy and Economics at USC, and Guest Scholar at the Brookings Institution Engleberg Center for Health Reform. Prior to Venrock, Bob served in the Obama Administration as Special Assistant to the President for Healthcare and Economic Policy on the National Economic Council. He also co-founded the Health Data Initiative with Todd Park, a joint effort of HHS and the Institute of Medicine, to release healthcare data to spur private sector innovation to improve healthcare cost and quality. Bob received undergraduate degrees from the University of Washington and a medical degree from George Washington University.
Julie Sunderland is a Managing Director of Biomatics Capital, a new $200mm venture capital fund investing in breakthrough science and technology that will transform the practice of medicine and delivery of healthcare, especially in the genomics and digital health sectors. Until recently, Ms. Sunderland was the Director of Program Related Investments for the Bill & Melinda Gates Foundation, where she was responsible for managing the foundation’s $1.5 billion program-related investment (PRI) pool which focuses on strategic investments in global health, global development, and US education. Ms. Sunderland founded the PRI program in 2009 as a $400 million pilot and grew the portfolio to 50 investments comprising a range of investment structures (equity, loans, guaranties, funds), sectors (biotech, health commodities, health delivery, agriculture, digital payments, charter schools, education technology), and geographies (US, Europe, Africa, India, China). She built and led a team of 10 investment professionals and chaired the foundation’s investment committee that reviews all program-related investments undertaken by the foundation. Ms. Sunderland holds a BA from Harvard University, an MBA from Wharton Business School and an MA from Johns Hopkins School of Advanced International Studies.
Jim Manzi is a founder and partner of Foundry.ai, a technology studio focused on conceptualizing and building AI application software businesses. He was founder, CEO and Chairman of Applied Predictive Technologies, which became the world’s largest purely cloud-based predictive analytics software company, and was sold to MasterCard in 2015. Previously, he worked at Bell Labs and as a corporate strategy consultant. Jim is the author of several software patents, as well as the 2012 book Uncontrolled, which has been widely reviewed in the New York Times, Wall Street Journal and other national publications. He received a B.S. in mathematics from MIT, and was subsequently awarded a Dean’s Fellowship in statistics to the doctoral program at the Wharton School of the University of Pennsylvania.
Aledade is backed by leading venture capital firms Venrock, ARCH Venture Partners, GV, Biomatics Capital Partners, and the Maryland Venture Fund. An established leader in health IT venture capital, Venrock’s investment is led by Bryan Roberts, lead investor in several health care companies valued at over $1 billion, and Dr. Bob Kocher, former special assistant to President Obama for health care and economic policy. Robert Nelsen, co-founder and managing director of ARCH Venture Partners, and Kristina Burow, managing director, have described Aledade as “uniquely positioned to help lead the U.S. health care system, with primary care physicians at the center of their patients’ care.” Biomatics Capital is a Seattle-based digital health and genomics focused venture capital firm, of which Julie Sunderland, former director at the Bill & Melinda Gates Foundation and Aledade Board member, was a founder. GV, formerly Google Ventures, is the venture capital arm of Alphabet, Inc. that provides funding to bold new companies that aim to improve lives and change industries. The Maryland Venture Fund is an early-stage, evergreen venture capital fund dedicated to funding and growing the next generate of outstanding businesses in Maryland.
Aledade is looking for experienced, dedicated employees who share our vision and passion for a new model of primary care. Visit our Careers page to learn more about employment opportunities and what it’s like to work at Aledade.